Pomerantz LLP filed a securities class action Wednesday in New Jersey District Court against Dublin-based biotech company Amarin Corporation PLC, its CEO John F. Thero and its CFO Michael W. Kalb. The lawsuit accuses the defendants of failing to disclose that there was an increasingly high risk that certain of Amarin’s patents would be invalidated during underlying patent litigations. Counsel have not yet appeared for the defendants. The case is 3:21-cv-19911, Dorfman v. Amarin Corporation PLC et al.
Biotech & Pharmaceuticals
November 10, 2021, 5:23 PM